Skip to main content

Advertisement

SpringerLink
Log in

Enhanced Endoscopy in Bladder Cancer

  • Urothelial Cancer (S Daneshmand, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

A Correction to this article was published on 05 April 2019

This article has been updated

Abstract

Purpose of Review

Endoscopy coupled with targeted resections represents a cornerstone in the diagnosis, staging, and treatment of patients with bladder cancer. Direct visualization can be challenging and imprecise due to patient-, tumor-, and surgeon-specific factors. We will review contemporary endoscopic technologies and techniques used to improve our ability to safely identify and resect malignant lesions in patients with bladder cancer.

Recent Findings

Enhanced endoscopic imaging technology may improve detection rates for bladder cancer throughout the upper and lower urinary tract, which may lead to improvements in recurrence and progression rates for non-muscle invasive bladder cancer (NMIBC). New techniques including narrow-band imaging (NBI), photodynamic diagnosis (PDD), Storz Professional Image Enhancement System (SPIES), optical coherence tomography (OCT), and others have shown benefit and may further improve our ability to detect and stage bladder tumors.

Summary

Enhanced endoscopy technologies have already demonstrated value in improving the sensitivity of bladder cancer detection and early results suggest they may improve short- and long-term oncologic outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Change history

  • 05 April 2019

    Author Siamak Daneshmand would like to note that this article published in Current Urology Reports inadvertently did not disclose financial information that could possibly be a conflict of interest.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance

  1. Siegel RL, Miller KD, Ahmedin J. Cancer statistics. CA Cancer J Clin. 2018;68(1):7–30.

    Article  PubMed  Google Scholar 

  2. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. PharmacoEconomics. 2003;21(18):1315–30.

    Article  PubMed  Google Scholar 

  3. Mossanen M, Gore JL. The burden of bladder cancer care: direct and indirect costs. Curr Opin Urol. 2014;24(5):487–91.

    Article  PubMed  Google Scholar 

  4. Mandalapu RS, Remzi M, de Reijke TM, Margulis V, Palou J, Kapoor A, et al. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. World J Urol. 2017;35(3):355–65.

    Article  CAS  PubMed  Google Scholar 

  5. •• Daneshmand S, Bazargani ST, Bivalacqua TJ, Holzbeierlein JM, Willard B, Taylor JM, et al. Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry. Urol Oncol Semin Orig Investig. 2018; available from: http://www.sciencedirect.com/science/article/pii/S1078143918301352. The authors of this study report outcomes for blue light cystoscopy (BLC) from a multicenter registry including over 1600 lesions from 533 patients. BLC improved the detection rate by 12%b for papillary lesions and 43% for carcinoma in situ. Twenty-five percent of patients had lesions detected only on BLC and BLC findings changed management in 14% of cases.

  6. Whitmore WF, Bush IM, Esquivel E. Tetracycline ultraviolet fluorescence in bladder carcinoma. Cancer. 1964;17:1528–32.

    Article  PubMed  Google Scholar 

  7. Bryan RT, Billingham LJ, Wallace DMA. Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder. BJU Int. 2008;101(6):702–5. discussion 705–706

    Article  PubMed  Google Scholar 

  8. Scott WW. The development of the cystoscope. From “lichtleiter” to fiber optics. Investig Urol. 1969;6(6):657–61.

    Google Scholar 

  9. Samplaski MK, Jones JS. Two centuries of cystoscopy: the development of imaging, instrumentation and synergistic technologies. BJU Int. 2009;103(2):154–8.

    Article  PubMed  Google Scholar 

  10. Nicholson P. Problems encountered by early endoscopists. Urology. 1982;19(1):114–9.

    Article  CAS  PubMed  Google Scholar 

  11. Gow JG. Harold Hopkins and optical systems for urology--an appreciation. Urology. 1998;52(1):152–7.

    Article  CAS  PubMed  Google Scholar 

  12. Zainfeld D, Daneshmand S. Transurethral resection of bladder tumors: improving quality through new techniques and technologies. Curr Urol Rep. 2017;18(5):34.

    Article  PubMed  Google Scholar 

  13. Cockett WS, Cockett AT. The Hopkins rod-lens system and the Storz cold light illumination system. Urology. 1998;51(5A Suppl):1–2.

    Article  CAS  PubMed  Google Scholar 

  14. Marcus SL, Sobel RS, Golub AL, Carroll RL, Lundahl S, Shulman DG. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): current clinical and development status. J Clin Laser Med Surg. 1996;14(2):59–66.

    Article  CAS  PubMed  Google Scholar 

  15. Kriegmair M, Baumgartner R, Riesenberg R, Jocham D, Sassy T, Stocker S, et al. Photodynamic diagnosis following topical application of delta-aminolevulinic acid in a rat bladder tumor model. Investig Urol Berl Ger. 1994;5:85–7.

    CAS  Google Scholar 

  16. Steinbach P, Kriegmair M, Baumgartner R, Hofstädter F, Knüchel R. Intravesical instillation of 5-aminolevulinic acid: the fluorescent metabolite 1s limited to urothelial cells. Urology. 1994;44(5):676–81.

    Article  CAS  PubMed  Google Scholar 

  17. Kriegmair M, Baumgartner R, Knuechel R, Steinbach P, Ehsan A, Lumper W, et al. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology. 1994;44(6):836–41.

    Article  CAS  PubMed  Google Scholar 

  18. Isfoss BL. The sensitivity of fluorescent-light cystoscopy for the detection of carcinoma in situ (CIS) of the bladder: a meta-analysis with comments on gold standard. BJU Int. 2011;108(11):1703–7.

    Article  PubMed  Google Scholar 

  19. Lerner SP, Liu H, Wu M-F, Thomas YK, Witjes JA. Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder. Urol Oncol. 2012;30(3):285–9.

    Article  PubMed  Google Scholar 

  20. Rink M, Babjuk M, Catto JWF, Jichlinski P, Shariat SF, Stenzl A, et al. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol. 2013;64(4):624–38.

    Article  PubMed  Google Scholar 

  21. • Chou R, Selph S, Buckley DI, Fu R, Griffin JC, Grusing S, et al. Comparative effectiveness of fluorescent versus white light cystoscopy for initial diagnosis or surveillance of bladder cancer on clinical outcomes: systematic review and meta-analysis. J Urol. 2017;197(3 Pt 1):548–58. This recent meta-analysis and systematic review published in the Journal of Urology found that fluorescent cystoscopy was associated with a reduced recurrence risk at short-, intermediate-, and long-term follow-up. Fluorescent cystoscopy with HAL was also associated with a lower risk of disease progression (RR 0.51, 95% CI 0.28–0.96).

    Article  PubMed  Google Scholar 

  22. Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, et al. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol. 2014;11(10):589–96.

    Article  CAS  PubMed  Google Scholar 

  23. Yuan H, Qiu J, Liu L, Zheng S, Yang L, Liu Z, et al. Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials. PLoS One. 2013;8(9):e74142.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Lee JY, Cho KS, Kang DH, Jung HD, Kwon JK, Oh CK, et al. A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging. BMC Cancer. 2015;15:566.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Gallagher KM, Gray K, Anderson CH, Lee H, Stewart S, Donat R, et al. “Real-life experience”: recurrence rate at 3 years with Hexvix® photodynamic diagnosis-assisted TURBT compared with good quality white light TURBT in new NMIBC-a prospective controlled study. World J Urol. 2017;35(12):1871–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Kamat AM, Cookson M, Witjes JA, Stenzl A, Grossman HB. The impact of blue light cystoscopy with hexaminolevulinate (HAL) on progression of bladder cancer - a new analysis. Bladder Cancer Amst Neth. 2016;2(2):273–8.

    Article  Google Scholar 

  27. Gakis G, Ngamsri T, Rausch S, Mischinger J, Todenhöfer T, Schwentner C, et al. Fluorescence-guided bladder tumour resection: impact on survival after radical cystectomy. World J Urol. 2015;33(10):1429–37.

    Article  CAS  PubMed  Google Scholar 

  28. Bach T, Bastian PJ, Blana A, Kaminsky A, Keller S, Knoll T, et al. Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III. World J Urol. 2017 May;35(5):737–44.

  29. Pagliarulo V, Alba S, Gallone MF, Di Stasi S, Cormio L, Petitti T, et al. Diagnostic Accuracy of Hexaminolevulinate in a Cohort of Patients Undergoing Radical Cystectomy. J Endourol. 2017;31(4):405–11.

  30. Drăgoescu PO, Tudorache Ş, Drocaş AI, Mitroi G, Pănuş A, Drăgoescu NAM, et al. Improved diagnosis and long-term recurrence rate reduction for non-muscle-invasive bladder cancer patients undergoing fluorescent hexylaminolevulinate photodynamic diagnosis. Romanian J Morphol Embryol Rev Roum Morphol Embryol. 2017;58(4):1279–83.

  31. • Kim SB, Yoon SG, Tae J, Kim JY, Shim JS, Kang SG, et al. Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: prospective, randomized comparison with white light cystoscopy. Investig Clin Urol. 2018;59(2):98–105. This randomized, prospective trial found that NBI improves detection rates of bladder cancer, but found no difference in the 1-year recurrence rates.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Drejer D, Béji S, Oezeke R, Nielsen AM, Høyer S, Bjerklund Johansen TE, et al. Comparison of white light, photodynamic diagnosis, and narrow-band imaging in detection of carcinoma in situ or flat dysplasia at transurethral resection of the bladder: the DaBlaCa-8 study. Urology. 2017;102:138–42.

    Article  PubMed  Google Scholar 

  33. •• Naito S, Algaba F, Babjuk M, Bryan RT, Sun Y-H, Valiquette L, et al. The Clinical Research Office of the Endourological Society (CROES) Multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in Primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. Eur Urol. 2016;70(3):506–15. This manuscript reports the 1-year follow-up results of a randomized, single-blind, multicenter study conducted by the Clinical Research Office of the Endourological Society. They found that recurrence rates 12 months after TURBT with WL compared to NBI were not significantly different overall. They did find that NBI reduced the risk of recurrence in patients with low-risk bladder cancer.

    Article  PubMed  Google Scholar 

  34. Apfelbeck M, Grimm T, Kretschmer A, Buchner A, Schneevoigt B-S, Jokisch F, et al. Follow-up of high-risk bladder cancer-Is it safe to perform fluorescence endoscopy multiple times in the same patient? Urol Oncol. 2017;35(10):602.e19–23.

    Article  Google Scholar 

  35. •• Daneshmand S, Patel S, Lotan Y, Pohar K, Trabulsi E, Woods M, et al. Efficacy and safety of blue light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: a phase iii, comparative, multicenter study. J Urol. 2018;199(5):1158–65. This prospective, multicenter study demonstrated that office-based flexible blue light cystoscopy improves the detection of recurrent bladder cancer by 21% and is safe to use for disease surveillance.

    Article  PubMed  Google Scholar 

  36. Osman E, Alnaib Z, Kumar N. Photodynamic diagnosis in upper urinary tract urothelial carcinoma: a systematic review. Arab J Urol. 2017;15(2):100–9.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Kata SG, Aboumarzouk OM, Zreik A, Somani B, Ahmad S, Nabi G, et al. Photodynamic diagnostic ureterorenoscopy: a valuable tool in the detection of upper urinary tract tumour. Photodiagn Photodyn Ther. 2016;13:255–60.

    Article  Google Scholar 

  38. Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009;27(3):295–300.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Witjes JA, Babjuk M, Gontero P, Jacqmin D, Karl A, Kruck S, et al. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. Eur Urol. 2014;66(5):863–71.

    Article  PubMed  Google Scholar 

  40. Gakis G, Volkmer B, Qvick B, Marteau F, Stenzl A. Cost-effectiveness analysis of blue light cystoscopy with hexylaminolevulinate in transurethral resection of the bladder. Urol Ausg A. 2018;

  41. Lerner SP, Goh A. Novel endoscopic diagnosis for bladder cancer. Cancer. 2015 Jan 15;121(2):169–78.

    Article  PubMed  Google Scholar 

  42. Xiong Y, Li J, Ma S, Ge J, Zhou L, Li D, et al. A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer. PLoS One. 2017;12(2):e0170819.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Kang W, Cui Z, Chen Q, Zhang D, Zhang H, Jin X. Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: a systematic review and meta-analysis. Oncotarget. 2017 Apr 4;8(14):23880–90.

    PubMed  Google Scholar 

  44. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196(4):1021–9.

    Article  PubMed  Google Scholar 

  45. Emiliani E, Talso M, Baghdadi M, Barreiro A, Orosa A, Serviàn P, et al. Evaluation of the spies TM modalities image quality. Int Braz J Urol Off J Braz Soc Urol. 2017;43(3):476–80.

    Article  Google Scholar 

  46. Kamphuis GM, de Bruin DM, Brandt MJ, Knoll T, Conort P, Lapini A, et al. Comparing image perception of bladder tumors in four different Storz Professional Image Enhancement System modalities using the íSPIES app. J Endourol. 2016;30(5):602–8.

    Article  PubMed  Google Scholar 

  47. Gravas S, Stenzl A. The Storz professional image enhancement system (SPIES) nonmuscle-invasive bladder cancer study:a multicenter international randomized controlled study. J Endourol. 2014;28(11):1254–5.

    PubMed  Google Scholar 

  48. Lurie KL, Smith GT, Khan SA, Liao JC, Ellerbee AK. Three-dimensional, distendable bladder phantom for optical coherence tomography and white light cystoscopy. J Biomed Opt. 2014;19(3). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951584/

  49. Ren H, Waltzer WC, Bhalla R, Liu J, Yuan Z, Lee CSD, et al. Diagnosis of bladder cancer with microelectromechanical systems-based cystoscopic optical coherence tomography. Urology. 2009;74(6):1351–7.

    Article  PubMed  Google Scholar 

  50. Manyak MJ, Gladkova ND, Makari JH, Schwartz AM, Zagaynova EV, Zolfaghari L, et al. Evaluation of superficial bladder transitional-cell carcinoma by optical coherence tomography. J Endourol. 2005;19(5):570–4.

    Article  PubMed  Google Scholar 

  51. Lingley-Papadopoulos CA, Loew MH, Manyak MJ, Zara JM. Computer recognition of cancer in the urinary bladder using optical coherence tomography and texture analysis. J Biomed Opt. 2008;13(2):024003.

    Article  PubMed  Google Scholar 

  52. Goh AC, Tresser NJ, Shen SS, Lerner SP. Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer. Urology. 2008;72(1):133–7.

    Article  PubMed  Google Scholar 

  53. Ren H, Yuan Z, Waltzer W, Shroyer K, Pan Y. Enhancing detection of bladder carcinoma in situ by 3-dimensional optical coherence tomography. J Urol. 2010;184(4):1499–506.

    Article  PubMed  Google Scholar 

  54. Ren H, Park KC, Pan R, Waltzer WC, Shroyer KR, Pan Y. Early detection of carcinoma in situ of the bladder: a comparative study of white light cystoscopy, narrow band imaging, 5-ALA fluorescence cystoscopy and 3-dimensional optical coherence tomography. J Urol. 2012;187(3):1063–70.

    Article  PubMed  Google Scholar 

  55. Huang J, Ma X, Zhang L, Jia H, Wang F. Diagnostic accuracy of optical coherence tomography in bladder cancer patients: a systematic review and meta-analysis. Mol Clin Oncol. 2018;8(4):609–12.

    Google Scholar 

  56. Schmidbauer J, Remzi M, Klatte T, Waldert M, Mauermann J, Susani M, et al. Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. Eur Urol. 2009;56(6):914–9.

    Article  PubMed  Google Scholar 

  57. Lingley-Papadopoulos CA, Loew MH, Zara JM. Wavelet analysis enables system-independent texture analysis of optical coherence tomography images. J Biomed Opt. 2009;14(4):044010.

    Article  PubMed  Google Scholar 

  58. Marvdashti T, Duan L, Aasi SZ, Tang JY, Ellerbee Bowden AK. Classification of basal cell carcinoma in human skin using machine learning and quantitative features captured by polarization sensitive optical coherence tomography. Biomed Opt Express. 2016;7(9):3721–35.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Canto MI, Anandasabapathy S, Brugge W, Falk GW, Dunbar KB, Zhang Z, et al. In vivo endomicroscopy improves detection of Barrett’s esophagus-related neoplasia: a multicenter international randomized controlled trial (with video). Gastrointest Endosc. 2014;79(2):211–21.

    Article  PubMed  Google Scholar 

  60. Marien A, Rock A, Maadarani KE, Francois C, Gosset P, Mauroy B, et al. Urothelial tumors and dual-band imaging: a new concept in confocal laser endomicroscopy. J Endourol. 2017;31(5):538–44.

    Article  PubMed  Google Scholar 

  61. Naya Y, Takaha N, Okubo T, Shiota K, Hayashi I, Mori M, et al. Probe-based confocal laser endomicroscopy using acrinol as a novel dye can be used to observe Cancer nuclei of bladder carcinoma in situ. J Endourol Case Rep. 2018;4(1):25–7.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Bui D, Mach KE, Zlatev DV, Rouse RV, Leppert JT, Liao JC. A pilot study of in vivo confocal laser endomicroscopy of upper tract Urothelial carcinoma. J Endourol. 2015;29(12):1418–23.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Liem EI, Freund JE, Baard J, de Bruin DM, Laguna Pes MP, Savci-Heijink CD, et al. Confocal laser endomicroscopy for the diagnosis of urothelial carcinoma in the bladder and the upper urinary tract: protocols for two prospective explorative studies. JMIR Res Protoc. 2018;7(2):e34.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Urology, USC Keck/Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Ave, Suite 7416, Los Angeles, CA, 90089, USA

    Shane Pearce & Siamak Daneshmand

Authors
  1. Shane Pearce
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Siamak Daneshmand
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shane Pearce.

Ethics declarations

Conflict of Interest

Shane Pearce declares no potential conflicts of interest.

Siamak Daneshmand is a section editor for Current Urology Reports.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Urothelial Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pearce, S., Daneshmand, S. Enhanced Endoscopy in Bladder Cancer. Curr Urol Rep 19, 84 (2018). https://doi.org/10.1007/s11934-018-0833-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11934-018-0833-9

Keywords

Search

Navigation